Company profile
Atavistik Bio
Precision allosteric therapeutics inspired by the body’s natural regulators
- Industry
- Biotechnology Research
- Employees
- 39
- Headquarters
- Cambridge, MA
- Founded
- 2021
- LinkedIn followers
- 4,267
- Office locations
- 1
Atavistik Bio company summary
Atavistik Bio is a company in the Biotechnology Research industry, headquartered in Cambridge, MA, founded in 2021. On LinkedIn the company has around 39 employees and 4,267 followers.
What technology does Atavistik Bio use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Atavistik Bio
Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics, with an internal focus on rare hematology. Atavistik Bio is advancing multiple programs with best-in-class potential, including the lead asset, ATV-1601, an oral allosteric AKT1-selective inhibitor for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and advancing a JAK2V617F mutant-selective inhibitor program for myeloproliferative neoplasms. Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, Nextech Invest, Lux Capital, Regeneron Ventures, and RA Capital Management.
Where is Atavistik Bio located?
Atavistik Bio lists 1 location.
Compare companies similar to Atavistik Bio
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Atavistik Bio atavistikbio.com | Biotechnology Research | 39 | 2021 | Cambridge, MA |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Atavistik Bio
What does Atavistik Bio do?
Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics, with an internal focus on rare hematology. Atavistik Bio is advancing multiple programs with best-in-class potential, including the lead asset, ATV-1601, an oral allosteric AKT1-selective inhibitor for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and advancing a JAK2V617F mutant-selective inhibitor program for myeloproliferative neoplasms. Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, Nextech Invest, Lux Capital, Regeneron Ventures, and RA Capital Management.
How many employees does Atavistik Bio have?
Atavistik Bio has around 39 employees on LinkedIn.
Where is Atavistik Bio headquartered?
Atavistik Bio is headquartered in Cambridge, MA.
When was Atavistik Bio founded?
Atavistik Bio was founded in 2021.
Build a lead list from companies like Atavistik Bio
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.